Latest Schedule 13G passive stakes

Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, have reported a 0.00% beneficial ownership of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 6.75% of Grace Therapeutics, Inc. common stock as of June 30, 2026.

RA Capital Management and its affiliates now beneficially own 9.9% of Geron Corporation's common stock, primarily through RA Capital Healthcare Fund, L.P., following an amendment to their Schedule 13G filing.

RA Capital Management, L.P. and related entities have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Fulcrum Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 1,862,250 shares, representing 3.54% of Avalo Therapeutics, Inc.'s common stock as of June 30, 2026.

Firefly Aerospace Inc. has filed an amendment to its Schedule 13G, detailing changes in beneficial ownership reporting for AeroEquity GP, LLC, Mitsui & Co., LTD., and Marc Allen Weiser.

Tango Therapeutics, Inc. has filed an amendment to its Schedule 13G, detailing beneficial ownership as of June 30, 2026, with reporting persons holding 0.0% of the class.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in InhibiKinase Therapeutics, Inc. as of June 30, 2026.

RA Capital Management, along with affiliated entities and individuals, has reported a beneficial ownership of 9.9% in C4 Therapeutics, Inc. as of June 30, 2026, primarily through warrants and common stock.

Caligan Partners LP and David Johnson have reported beneficial ownership of 5.9% of Avalo Therapeutics, Inc. common stock as of June 30, 2026.

Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz have jointly filed a Schedule 13G, reporting no beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026.

Alyeska Investment Group, L.P. and its affiliates have reported a beneficial ownership of 6.74% in Globant S.A. common shares as of June 30, 2026.

RA Capital Management, along with affiliated entities and individuals, has reported beneficial ownership of 3,483,099 shares, representing 6.3% of Avalo Therapeutics, Inc.'s common stock.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 5,475,040 shares, representing 8.22% of Fulcrum Therapeutics, Inc.'s common stock as of June 30, 2026.

RA Capital Management and its affiliates report maintaining a 9.9% beneficial ownership in Adicet Bio, Inc. as of June 30, 2026, primarily through RA Capital Healthcare Fund, L.P.

Alyeska Investment Group, L.P., along with its affiliates, has reported beneficial ownership of 5.08% of Forward Industries, Inc. common stock, acquiring shares through a private placement and pre-funded warrants.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed beneficial ownership of 400,000 shares, representing 9.91% of Eloxx Pharmaceuticals' common stock as of June 30, 2026.

Fourthstone LLC and affiliated entities have updated their beneficial ownership filing for Eagle Financial Services Inc., reporting a combined 5.31% stake.

Lightspeed Venture Partners has filed a Schedule 13G, detailing their beneficial ownership of Rubrik, Inc. Class A common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its principals Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 9.99% of Azitra, Inc.'s common stock as of June 30, 2026.

RA Capital Management, along with affiliated entities and individuals, has reported a beneficial ownership of 9.1% of Aclaris Therapeutics' common stock as of June 30, 2026.

Several Lightspeed Venture Partners entities have filed a Schedule 13G, detailing their collective beneficial ownership of Netskope, Inc. Class A common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 9.69% of ADC Therapeutics SA's common shares as of June 30, 2026.

First Light Asset Management, LLC and Mathew P. Arens report increased beneficial ownership of Axogen, Inc. common stock, now holding approximately 7.58%.

Lynx1 Capital Management LP and Weston Nichols have reported beneficial ownership of 13.1% of TScan Therapeutics, Inc. common stock as of June 30, 2026.

Platinum Equity entities and Tom Gores have collectively adjusted their beneficial ownership of Ryerson Holding Corporation's common stock to 3.7%, reporting shared voting and dispositive power over 1,924,478 shares.

Several KKR-affiliated entities and individuals have filed a joint Schedule 13G statement, disclosing beneficial ownership of over 81% of GMR Solutions Inc.'s Class A common stock.

Disciplined Growth Investors Inc. has updated its Schedule 13G filing to reflect its beneficial ownership of Powerfleet, Inc. common stock.

Austin Meyer has increased his beneficial ownership of BETA Technologies' Class A Common Stock to 5.4%, holding over 12 million shares.

Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 13,263,288 ordinary shares, representing 19.3% of GH Research PLC.